PolyPid (FRA:2PV) EV-to-FCF: (As of Jun. 26, 2026)


FRA:2PV PolyPid Ltd FRA:2PV
14 GF Score
Price €3.99
! 1 Warning Sign
View Full Analysis

What is PolyPid EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PolyPid's Enterprise Value is €69.80 Mil. PolyPid's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil. Therefore, PolyPid's EV-to-FCF for today is .

The historical rank and industry rank for PolyPid's EV-to-FCF or its related term are showing as below:

FRA:2PV' s EV-to-FCF Range Over the Past 10 Years
Min: -2.82   Med: 0   Max: 0
Current: -2.82

FRA:2PV's EV-to-FCF is ranked worse than
100% of 333 companies
in the Biotechnology industry
Industry Median: 14.65 vs FRA:2PV: -2.82

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-26), PolyPid's stock price is €3.985. PolyPid's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.644. Therefore, PolyPid's PE Ratio (TTM) for today is At Loss.


PolyPid  (FRA:2PV) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PolyPid's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.985/-1.644
=At Loss

PolyPid's share price for today is €3.985.
PolyPid's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.644.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


PolyPid EV-to-FCF Related Terms


PolyPid EV-to-FCF Historical Data

* Premium members only.

The historical data trend for PolyPid's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPid EV-to-FCF Chart

PolyPid Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.13 -0.42 -0.73 -1.13 -2.45

PolyPid Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.45 0.00

FRA:2PV vs LONA, ANIX, SGMO: EV-to-FCF Comparison

For the Biotechnology subindustry, PolyPid's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPid EV-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PolyPid's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where PolyPid's EV-to-FCF falls into.


FRA:2PV
14GF Score
PolyPid Ltd FRA:2PV
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPid EV-to-FCF Calculation

PolyPid's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=69.803/0
=

PolyPid's current Enterprise Value is €69.80 Mil.
PolyPid's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPid Business Description

Other Exchanges PYPD:USA
Address 18 Hasivim Street, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
14GF Score

Get the complete analysis for FRA:2PV

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.99
Price